About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 155 entries.

Entries by Haley Chartres

Research Report by Euroz Hartleys – 14 October 2022

October 14, 2022 in , , /by

Botanix is pleased to share a recent analyst report published by Euroz Hartleys following last week’s announcement of positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea.  Analyst Seth Lizee noted: “We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver […]

Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea

October 12, 2022 in , , /by

Botanix has released positive data from its BTX1702 rosacea clinical study.  The Phase 1b/2 randomised, double-blind vehicle-controlled study examined the effects Botanix’s CBD formulation BTX 1702 in adults with moderate to severe papulopustular rosacea over an 8-week treatment period. The study tested two different concentrations of BTX 1702 topical gel – 10% and 20% – […]

Botanix submits NDA for FDA approval of Sofpironium Bromide

September 26, 2022 in , , /by

Botanix has today announced the submission of a New Drug Application to the FDA for approval of Sofpironium Bromide for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating). Phase 3 studies of Sofpironium Bromide showed very high statistical significance for the treatment of primary axillary hyperhidrosis. In the US alone, there are approximately […]

Capital Raise Update

September 12, 2022 in , , /by

Botanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors. The second tranche of the Placement is an issue of New Shares to Botanix directors, who have  committed to subscribe for a total of $0.5 million of New Shares, which is […]

$7.5m Capital Raise

September 2, 2022 in , , /by

Botanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors. Funds will support the development of the Company’s lead asset – Sofpironium Bromide (SB) – a novel dermatology asset with positive Phase 3 data to treat primary axillary hyperhidrosis, a medical condition […]

Research Report by Euroz Hartleys – 17 August 2022

August 17, 2022 in , , /by

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide. Within the report, analyst Seth Lizee commented: “Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated […]

Euroz Hartleys Report | 7 July 22

July 7, 2022 in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company announcement that the FDA filing timeline for Sofpironium Bromide had been accelerated. Click here to view the report.

NDA filing accelerated and trials fully enrolled

July 7, 2022 in , /by

Botanix has today announced the New Drug Approval (NDA) submission to the FDA for our recently acquired dermatology asset, Sofpironium Bromide for the treatment of excessive underarm sweating, will now be ready to file in Q3 2022. The Company also provided an update on its pipeline clinical studies. Both the rosacea (BTX1702) Phase 1/2 clinical […]